Healthcare Industry News: Alzheimer’s disease
News Release - January 8, 2009
Howard Feldman Joins Bristol-Myers Squibb as Vice President and Therapeutic Area Head, Global Clinical Research, NeurosciencePRINCETON, N.J., January 08, 2009 - (HSMN NewsFeed) - Bristol-Myers Squibb Company (NYSE: BMY) today announced that Dr. Howard Feldman has joined the company's Research and Development organization as vice president and therapeutic area head, Global Clinical Research, Neuroscience. He will report to Dr. Doug Manion, vice president, Global Clinical Research, Neuroscience and Virology.
"I am pleased Howard has joined our R&D organization as we look to further build our robust pipeline in areas of significant unmet medical need in neuroscience," said Brian Daniels, M.D., Senior Vice President, Global Development & Medical Affairs. "Howard’s renowned expertise in behavioral neurology and Alzheimer’s disease will help ensure we remain a leader in helping patients prevail against serious disease, specifically neurological and psychiatric disorders, by leading clinical research strategy in both areas.”
Prior to joining Bristol-Myers Squibb, Dr. Feldman served as Professor and Head of the Division of Neurology, University of British Columbia (UBC) and Vancouver Coastal Health, Vancouver, Canada. He was also the Director of the Clinic for Alzheimer Disease and Related Disorders at UBC Hospital and held an appointment as Adjunct Professor at the McGill Centre for Studies in Aging in Montreal. In his research activities, Dr. Feldman has focused on epidemiological and clinical diagnostic/therapeutic studies in cognition with aging, the dementias and Alzheimer’s disease. He has been the principal investigator on a number of seminal international clinical trials with experimental therapies for Alzheimer’s disease.
Dr. Feldman’s contributions to the dementia field also include key scientific discoveries in the area of frontotemporal dementia (FTD) where he was involved in the discovery of the progranulin gene causing FTD as well as the identification of TDP (transactive response DNA-binding protein) as a constitutional protein in this disorder. These discoveries were published in Science and Nature in 2006.
Dr. Feldman received his Medical Degree from McGill University in 1978. He completed his residency training in Internal Medicine at the Royal Victoria Hospital in Montreal, Quebec, and Neurology at the University of Colorado and the University of British Columbia. He went on to a fellowship in Neuromuscular Diseases and Amyotrophic Lateral Sclerosis at the University of British Columbia in 1986 receiving his FRCP(C) in Neurology. Dr. Feldman has published more than 100 peer-reviewed papers and has numerous other scholarly contributions including a text entitled the Atlas of Alzheimer’s disease. He has lectured globally and has been the recipient of numerous awards and distinctions including a career profile in Lancet Neurology in 2007.
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to extend and enhance human life. For more information visit www.bms.com
Source: Bristol-Myers Squibb
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.